Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis
Diabetes Mellitus
About this trial
This is an interventional treatment trial for Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
Patients age >18 year with previous diagnosis of Diabetes Mellitus and previous admission for DKA in any facility within the prior 2 years who meet the criteria for DKA at the time of admission and are willing to participate in the study protocol will be enrolled in the study.
DKA is defined as:
- Serum bicarbonate below 18 mg/dl
- Anion Gap over greater than or equal to 16
- Serum ketones or beta hydroxybutyrate elevation > 3 mmol/L
- Serum glucose greater than or equal to 250 mg/dl
Exclusion Criteria:
Patients with no previous DKA, patients who are not willing to consent to participate in the study protocol for 1 year, pregnant women, dementia, and end stage renal disease on dialysis.
-
Sites / Locations
- Hennepin County Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Degludec
Standard long-acting
Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR <30 ml/hr.
Discharge on 0.3 U/kg of admission long acting insulin glargine or detemir (provided by diabetes and endocrine clinic) regardless of their home insulin regimen at the time of admission with reduction to 0.2 U/kg in CKD with GFR <30 ml/hr.